HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?

Abstract
Despite the poor survival of patients with advanced (stage IIIB with pleural effusion or stage IV) non-small-cell lung cancer, the introduction of new chemotherapeutic agents has improved survival and quality of life with reduced toxicity compared with older cisplatin-based therapies. Randomized trials support the use of two-drug combinations for patients of all ages with performance status of 0 to 1. These two-drug combinations should contain at least one new agent. Some of these two-drug combinations may be acceptable in selected patients with a performance status of 2. Newer, targeted therapies hold promise to improve outcome without adding a great deal of additional toxicity.
AuthorsPaul A Bunn Jr
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 20 Issue 18 Suppl Pg. 23S-33S (Sep 15 2002) ISSN: 0732-183X [Print] United States
PMID12235221 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S., Review)
Chemical References
  • Deoxycytidine
  • Vinblastine
  • Irinotecan
  • Cisplatin
  • Vinorelbine
  • Camptothecin
  • Gemcitabine
Topics
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Camptothecin (administration & dosage, analogs & derivatives)
  • Carcinoma, Non-Small-Cell Lung (drug therapy, pathology)
  • Cisplatin (administration & dosage)
  • Deoxycytidine (administration & dosage, analogs & derivatives)
  • Humans
  • Irinotecan
  • Lung Neoplasms (drug therapy, pathology)
  • Neoplasm Staging
  • Palliative Care
  • Randomized Controlled Trials as Topic
  • Vinblastine (administration & dosage, analogs & derivatives)
  • Vinorelbine
  • Gemcitabine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: